Butterfly, Graham, Wise Equity target nutraceuticals; Demand for antimicrobial testing drives Astorg’s $1bn carve-out of Thermo Fishers’ microbiology biz

Butterfly Equity, Graham Partners and Wise Equity are among the firms transacting with nutraceuticals assets.